{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:02:57Z","timestamp":1790488977058,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ijantimicag.2020.106186","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T11:12:10Z","timestamp":1602241930000},"page":"106186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Antibody-based strategies in HIV therapy"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-096X","authenticated-orcid":false,"given":"Wesley D.","family":"Kufel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106186_bib0001","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1038\/s41598-018-21081-x","article-title":"Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009\u20132016: a nationwide study","volume":"8","author":"Kim","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0002","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40265-020-01284-1","article-title":"Advances in long-acting agents for the treatment of HIV infection","volume":"80","author":"Rana","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0003","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/COH.0000000000000479","article-title":"The return of PRO 140, a CCR5-directed mAb","volume":"13","author":"Thompson","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0004","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1089\/aid.2019.0063","article-title":"Trends in HIV-1 drug resistance mutations from a U.S. reference laboratory from 2006 to 2017","volume":"35","author":"Kagan","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0005","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1371\/journal.pmed.0030356","article-title":"Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART","volume":"3","author":"Hogg","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0006","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/01.aids.0000174455.01369.ad","article-title":"Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients","volume":"19","author":"Zaccarelli","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0007","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/jac\/dkm522","article-title":"What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?","volume":"61","author":"Grover","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0008","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2174\/138920108786786358","article-title":"Monoclonal antibodies as innovative therapeutics","volume":"9","author":"Reichert","year":"2008","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0009","doi-asserted-by":"crossref","first-page":"e00110","DOI":"10.1128\/AAC.00110-19","article-title":"Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection","volume":"63","author":"Beccari","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0010","series-title":"Trogarzo (ibalizumab-uiyk): highlights of prescribing information","author":"Biologics","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0011","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3389\/fmicb.2017.02323","article-title":"Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy","volume":"8","author":"Iacob","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0012","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0013","doi-asserted-by":"crossref","first-page":"15279","DOI":"10.1074\/jbc.M114.628610","article-title":"The V4 and V5 variable loops of HIV-1 envelope glycoprotein are tolerant to insertion of green fluorescent protein and are useful targets for labeling","volume":"290","author":"Nakane","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0014","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/AAC.00942-08","article-title":"Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults","volume":"53","author":"Jacobson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0015","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1086\/380802","article-title":"Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1","volume":"189","author":"Kuritzkes","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0016","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/clim.2000.4975","article-title":"Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees","volume":"98","author":"Newman","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0017","series-title":"Conference on Retroviruses and Opportunistic Infections","article-title":"Ibalizumab susceptibility in patient HIV isolates resistant to antiretrovirals","author":"Weinheimer","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0018","series-title":"International AIDS Conference","article-title":"TNX-355 in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in phase 2 study at 48 weeks","author":"Norris","year":"2006"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0019","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Safety, efficacy, and pharmacokinetics of ibalizumab in treatment-experienced HIV-1-infected patients: a phase 2b study","author":"Khanlou","year":"2011"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2020.106186_bib0020","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1093\/ofid\/ofx162.093","article-title":"Forty-eight-week safety and efficacy on-treatment analysis of ibalizumab in patients with multi-drug resistant HIV-1","volume":"4","author":"Emu","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0021","series-title":"Conference on Retroviruses and Opportunistic Infections","article-title":"Comparable efficacy of ibalizumab in combination with 1 or 2 fully active agents","author":"DeJesus","year":"2020"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0b013e3182732746","article-title":"Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope","volume":"62","author":"Pace","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0023","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1128\/JVI.02237-10","article-title":"Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab","volume":"85","author":"Toma","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0024","series-title":"Conference on Retroviruses and Opportunistic Infections","article-title":"Intramuscular ibalizumab: pharmacokinetics, safety, and efficacy versus IV administration","author":"Lin","year":"2017"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0025","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1086\/592169","article-title":"Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults","volume":"198","author":"Jacobson","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0026","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1128\/JVI.73.5.4145-4155.1999","article-title":"Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5","volume":"73","author":"Olson","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0027","series-title":"International AIDS Conference","article-title":"CCR5 monoclonal antibody PRO 140 inhibited HIV-1 resistant to maraviroc, a small molecule CCR5 antagonist","author":"Marozsan","year":"2008"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0028","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1128\/AAC.00699-06","article-title":"Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1","volume":"50","author":"Murga","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0029","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/652190","article-title":"Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody","volume":"201","author":"Jacobson","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0030","series-title":"ClinicalTrials.gov","article-title":"A phase 2b study to assess suppression of HIV-1 replication following substitution of stable combination antiretroviral therapy with a PRO 140 (monoclonal CCR5 antibody) monotherapy in adult subjects with HIV-1 infection","year":"2014"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0031","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1128\/AAC.00086-10","article-title":"Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults","volume":"54","author":"Jacobson","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0032","series-title":"Conference on Retroviruses and Opportunistic Infections","article-title":"Prolonged coating of CCR5 lymphocytes by PRO 140, a humanized CCR5 monoclonal antibody for HIV-1 therapy","author":"Olson","year":"2006"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0033","series-title":"ClinicalTrials.gov","article-title":"A randomized, double-blind, placebo-controlled trial, followed by single-arm treatment of PRO 140 in combination with optimized background therapy in treatment-experienced HIV subjects","year":"2015"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0034","series-title":"ClinicalTrials.gov","article-title":"A phase 2b\/3, multicenter study to assess the treatment strategy of using PRO 140 SC as long-acting single-agent maintenance therapy for 48 weeks in virologically suppressed subjects with CCR5-tropic HIV-1 infection","year":"2016"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15284336.2018.1452842","article-title":"PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection","volume":"19","author":"Dhody","year":"2018","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0036","series-title":"CytoDyn's PRO 140 (leronlimab) HIV monotherapy trial results show 92% responder's rate at 700 mg dose, GlobeNewswire. Omaha, NE, USA","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0037","series-title":"CytoDyn reports primary endpoint achieved in PRO 140 pivotal combination therapy trial in HIV infection, CytoDyn. Vancouver, WA, USA","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0038","series-title":"CytoDyn announces positive results from completed pivotal PRO 140 HIV combination trial, CytoDyn. Vancouver, WA, USA","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0039","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Subcutaneous ibalizumab in at-risk healthy subjects","author":"Ernst","year":"2014"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0040","volume":"Irvine, CA","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.106186_bib0041","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0000000000002241","article-title":"Clinical and economic impact of ibalizumab for people with multidrug-resistant HIV in the United States","volume":"83","author":"Millham","year":"2020","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920303927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920303927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:36:35Z","timestamp":1760376995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920303927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0924857920303927"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106186","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-based strategies in HIV therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106186"}}